Aprameya Enginee Q4 FY25 Share Price & Earnings Call Analysis

Financials of Aprameya Enginee

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Financials of Aprameya Enginee

Quarterly Results

Quarter-by-quarter operating performance

No quarterly results data available for this company yet.

Financials of Aprameya Enginee

Profit & Loss

Annual income statement trend

Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales +1226357865136169
Expenses +1124256959111132
Operating Profit2210962437
OPM %13%9%29%12%10%18%22%
Other Income +0000010
Interest1102234
Depreciation0000000
Profit before tax1210752233
Tax %8%44%25%28%24%26%
Net Profit +117531625
EPS in Rs10.663.842.498.4712.92
Dividend Payout %0%0%0%0%0%0%

Financials of Aprameya Enginee

Balance Sheet

Capital structure and asset base

Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital44714141919
Reserves007694552
Borrowings +411429423037
Other Liabilities +652013104926
Total Liabilities1411496276144135
Fixed Assets +1121111
CWIP0000000
Investments0000000
Other Assets +1310476074143133
Total Assets1411496276144135

Financials of Aprameya Enginee

Cash Flows

Operating, investing and financing cash movement

Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity +0410-13-10-11
Cash from Investing Activity +-10-0-2-1-0
Cash from Financing Activity +1-4-8131111
Net Cash Flow0-02-20-0
Free Cash Flow-0410-14-11-11
CFO/OP22%173%149%-115%-133%-28%

Financials of Aprameya Enginee

Ratios

Working capital efficiency and return ratios

Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days18258278195325320
Inventory Days24512245537674
Days Payable2691471,100415146
Cash Conversion Cycle15933-367157253320
Working Capital Days4036200116153166
ROCE %35%59%25%12%31%

What Aprameya Enginee's management said in earlier quarters

Others in Healthcare Equipment & Supplies this season

  • QMS Medical (Q1 FY27)

    Contract renewals historically exhibit a 60-70% roll-over rate annually, ensuring revenue visibility from existing clients. Key concall takeaways from QMS…

  • Laxmi Dental (Q1 FY27)

    PAT grew 23.8% y-o-y in Q1 FY27, showing healthy bottom-line growth (Page 4). Key concall takeaways from Laxmi Dental Ltd's Q1 FY27 earnings call — and how it…

  • Tarsons Products (Q2 FY26)

    Plastic labware market is expanding faster than glass, currently at INR1,200 crores, signaling long-term sector growth opportunities. Key concall takeaways…

  • Vaidya Sane (Q2 FY26)

    Ongoing construction and CAPEX of about INR 25-30 crores for capacity expansion at Khopoli and Nagpur hospitals. Key concall takeaways from Vaidya Sane's Q2…

Compare:vs Poly Medicurevs Molbio Diagnostivs Fischer Medical